AstraZeneca expands biologics manufacturing in the USA by buying Amgen site
Anglo-Swedish drug major AstraZeneca (LSE: AZN) has expanded its biologics manufacturing capabilities in the USA by purchasing a manufacturing facility from Amgen (Nasdaq: AMGN).
The LakeCentre facility in Boulder, Colorado, will increase AstraZeneca’s manufacturing and production capacity in biologics. The company will start staffing the plant immediately, supporting refurbishment and infrastructure improvements, and the site is expected to be operational and licensed by late 2017.
The site is expected to create up to 400 skilled jobs, subject to approvals by local authorities. It will double the biologics manufacturing capacity to meet the needs of AstraZeneca’s pipeline, of which biologics make up 50% at present. There are more than 120 ongoing biologics programs and more than 30 in clinical development.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze